Clinical Trial Update: Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of pazopanib, irinotecan, and cetuximab for second-line metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)
• Votrient (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Colorectal | Phase 1 | Status: COMPLETED